The industry has reached a tipping point with regard to women in higher-ranking positions, said Wende Hutton, general partner with venture capital (VC) firm Canaan Partners.
"Maybe 10 years ago, you would have looked around an executive team and there would have been one woman in regulatory affairs, or one who is a chief financial officer, or one who is the head of marketing," Hutton said. Lately, they're showing up as chief medical officers and vice presidents of R&D. Canaan's portfolio includes 12 CEOs who are women.
This week, the VC made public its 10th fund, Canaan X, which drew $675 million in commitments, with one-third dedicated to health care and the rest to information technology, as with previous Canaan funds. The VC now has more than $4.2 billion under management.
About women in biotech, "we just haven't seen that level of talent move all the way up the ranks before, and very much on the technical side of the house